RATIO-ACYCLOVIR TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
07-08-2013
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
ACYCLOVIR
Tilgængelig fra:
TEVA CANADA LIMITED
ATC-kode:
J05AB01
INN (International Name):
ACYCLOVIR
Dosering:
400MG
Lægemiddelform:
TABLET
Sammensætning:
ACYCLOVIR 400MG
Indgivelsesvej:
ORAL
Enheder i pakken:
100
Recept type:
Prescription
Terapeutisk område:
NUCLEOSIDES AND NUCLEOTIDES
Produkt oversigt:
Active ingredient group (AIG) number: 0115506004; AHFS:
Autorisation status:
CANCELLED POST MARKET
Autorisation dato:
2018-05-18
Produktets egenskaber
_ _
_Product Monograph _RATIO-ACYCLOVIR_ _
_Page 1 of 39_
_ _
_ _
_ _
_ _
PRODUCT MONOGRAPH
PR
RATIO-ACYCLOVIR
acyclovir
Tablets USP, 200 mg, 400 mg and 800 mg
Antiviral Agent
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Date of Preparation :
July 24, 2013
Submission Control No: 166251
_ _
_Product Monograph _RATIO-ACYCLOVIR_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
6
DRUG INTERACTIONS
....................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
10
OVERDOSAGE
................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 12
STORAGE AND STABILITY
.........................................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 14
PART II: SCIENTIFIC
INFORMATION...............................................................................
16
PHARMACEUTICAL INFORMATION
.........................................................................
16
CLINICAL TRIALS
..........................................................................................
Læs hele dokumentet
